Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Calla Lily Clinical Care join Wellcome Leap’s antibiotics programme

Published

on

""

Calla Lily Clinical Care, a women’s health-focused medical technology company, has joined Wellcome Leap’s Focused Antibiotics programme – a new $50m funded programme to transform how antibiotics are delivered and address the growing global threat of antimicrobial resistance (AMR).

Founded by the Wellcome Trust in 2020, US non-profit Wellcome Leap runs research programmes such as Focused Antibiotics, which aims to develop targeted treatments that tackle infections while preserving the gut microbiome.

Antimicrobial resistance (AMR) is projected to contribute to more than 8 million deaths annually by 20501, with systemic antibiotic use contributing to gut damage and the spread of resistant bacteria. Women are disproportionately affected, receiving almost 40% more antibiotics than men between the ages of 16 and 54, largely due to the prevalence of urinary tract infections2.

Calla Lily Clinical Care has been selected by Wellcome Leap to deliver antibiotics directly via the vaginal wall, bypassing GI transit and first-pass metabolism, and expected to confine systemic exposure to under 5%. Currently, no first-line UTI antibiotic is available in a mass-manufactured vaginal formulation and, if successful, this project will support the programme’s broader objectives of reducing antibiotic-driven resistant infections by up to 40% per year.

Callavid has developed a leak-free, tampon-like platform for delivering vaginal medicines and hormones. Its NIHR-funded FREEDOM trial, launched in April 2026, is evaluating vaginal progesterone delivery, with the study having passed its safety stopping rule and 90% of patients completing the first dosing round.

Dr Lara Zibners, Co-founder and Chair of Calla Lily Clinical Care, added: “Women are disproportionately impacted by urinary tract infections, yet the consequences of that repeated systemic exposure have been largely overlooked. Organisations such as Wellcome Leap play a vital role in tackling major healthcare challenges through bold innovation.”

Thang Vo-Ta, Co-founder and CEO of Calla Lily Clinical Care, said: “The Focused Antibiotics programme gives us the ideal partner to pursue one of the most consequential of those indications: treating the world’s most common bacterial infection in women while helping to address a global resistance crisis that, left unchecked, could claim eight million lives annually by 2050. This marks a pivotal moment in demonstrating that when you solve for women, you solve for everyone.”

The project will be led by Dr Serena de Gelidi, Principal Investigator and R&D Manager at Calla Lily Clinical Care, who holds a PhD in Biomechanical Engineering and brings over thirteen years of medical device research experience, including work on the EU Horizon 2020-funded CRADL device for premature infants. She is supported by Professor Andrew Lewis, Principal Scientist at Calla Lily and an international authority on drug-eluting systems with 58 patents and over 260 peer-reviewed publications.

The post Calla Lily Clinical Care join Wellcome Leap’s antibiotics programme appeared first on Drug Discovery World (DDW).

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read